



HAL
open science

Impact of endometriosis on oocyte morphology in IVF-ICSI: retrospective study of a cohort of more than 6000 mature oocytes

C. Robin, A. Uk, C. Decanter, Helene Behal, Pierre Collinet, Chrystelee Rubod
Dit Guillet, Anne-Laure Barbotin, Geoffroy Robin

► To cite this version:

C. Robin, A. Uk, C. Decanter, Helene Behal, Pierre Collinet, et al.. Impact of endometriosis on oocyte morphology in IVF-ICSI: retrospective study of a cohort of more than 6000 mature oocytes. *Reproductive Biology and Endocrinology*, 2021, *Reproductive Biology and Endocrinology*, 19 (160), 10.1186/s12958-021-00798-x . hal-04502199

HAL Id: hal-04502199

<https://hal.univ-lille.fr/hal-04502199>

Submitted on 13 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



Impact of endometriosis on oocyte morphology in IVF-ICSI: retrospective study of a cohort of more than 6000 mature oocytes

Camille Robin^{1*}, Audrey Uk², Christine Decanter^{1,3}, H  l  ne Behal⁴, Pierre Collinet^{5,6}, Chryst  le Rubod^{5,6}, Anne-Laure Barbotin^{2,3,6} and Geoffroy Robin^{1,3,6}

Abstract

Background: Infertility associated with endometriosis can be explained by several non-exclusive mechanisms. The oocyte plays a crucial role in determining embryonic competence and this is particularly relevant for in vitro fertilization (IVF) outcomes. According to some authors, the morphology of oocytes could also be a non-invasive marker of oocyte quality. The aim of this study was to evaluate the relationship between endometriosis and oocyte morphology after controlled ovarian stimulation for intracytoplasmic sperm injection (ICSI) on a large oocyte cohort.

Methods: Single-center comparative retrospective study in the academic In Vitro Fertilization (IVF) unit of the Lille University Hospital. A total of 596 women treated for IVF-ICSI with ejaculated spermatozoa for sperm alterations were included. They were classified as endometriosis (n = 175) or control groups (n = 401). The morphological evaluation of 2,016 mature oocytes from 348 cycles of patients with endometriosis was compared with that of 4,073 mature oocytes from 576 control cycles. The main outcome measures were Average Oocyte Quality Index (AOQI) and metaphase II oocyte morphological scoring system (MOMS). Comparison of groups was carried out by a mixed linear model and by a generalized estimation equation model with a "patient" random effect to consider that a patient might have several attempts.

Results: No difference in AOQI and MOMS scores was found between endometriosis and control women (*adjusted p* = 0.084 and 0.053, respectively).

In case of endometriosis, there were significantly fewer metaphase II oocytes retrieved, embryos obtained, grade 1 embryos and number of cumulative clinical pregnancies compared to controls. In the endometriosis group, endometriosis surgery was associated with a reduced number of mature oocytes retrieved, and the presence of endometrioma(s) was associated with some abnormal oocyte shapes. Nevertheless, no difference concerning the AOQI and MOMS scores was found in these subgroups.

Conclusion: Endometriosis does not have a negative impact on oocytes' morphology in IVF-ICSI.

*Correspondence: camille.robin@chru-lille.fr

¹ Service de Gyn  cologie Endocrinienne Et M  decine de La Reproduction, CHU Lille, Assistance M  dicale    La Procr  ation Et Pr  servation de La Fertilit  , H  pital Jeanne de Flandre, Service d'Avenue Eug  ne Avin  e, 59000 Lille, France

Full list of author information is available at the end of the article



   The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Trial registration: On December 16, 2019, the Institutional Review Board of the Lille University Hospital gave unrestricted approval for the anonymous use of all patients' clinical, hormonal and ultrasound records (reference DEC20150715-0002).

Keywords: Endometriosis, Oocyte morphology, In vitro fertilization, Oocyte quality, Endometrioma

Background

Endometriosis is characterized by the presence of endometrial glands or stroma outside the uterine cavity [1, 2]. It would affect about 10–15% of women aged 15–49 years-old and 25–50% of patients managed for infertility [3–5]. The American Fertility Society classification (AFS classification), based on laparoscopic results, is the most widely used to define the severity of the pathology [6]. However, this anatomical classification does not allow describing deep endometriosis correctly [7]. It is also poorly predictive of chances of spontaneous or induced pregnancy and has little correlation with the severity of the symptoms presented by the patients [7]. Many pathophysiological hypotheses for endometriosis exist and clarify the heterogeneity of its localizations [1, 2, 8–10]. Most pathologists suggest a probable combination of the different hypotheses. Endometriosis is thus a multifactorial disease, resulting from the combined action of genetic, hormonal, immunological, angiogenic and environmental factors [1, 2, 9–11].

Infertility associated with endometriosis can be explained by several non-exclusive mechanisms: organic damage to certain organs such as the fallopian tubes, chronic inflammation of the pelvic cavity, which can disrupt gamete survival and fertilization, disruption of the physiological processes of implantation, ovarian abnormalities (alteration of the quantity and/or quality of the oocyte, potential alteration of the oocyte microenvironment in women with endometriosis related to a variation of the cytokine expression profile) [4, 11–15].

The oocyte plays a crucial role in determining embryonic competence and this is particularly relevant for in vitro fertilization (IVF) outcomes [16]. For ethical reasons, oocyte quality has generally been studied indirectly by non-invasive procedures such as the evaluation of the cumulus cells surrounding the oocytes and/or the analysis of follicular fluid [5]. However, it is not certain that these approaches truly reflect the quality and competence of the oocyte [5]. According to some authors, the morphology of oocytes could also be a non-invasive marker of oocyte quality [16–20]. Thus, Van Blerkom and Henry's work [20] hypothesized that oocyte quality may be related to certain morphological irregularities easily identifiable by light microscopy [16, 20]. Oocyte morphology is evaluated by analysis of cumulus cells, nuclear maturation, as well as the appearance of the cytoplasm

and extra-cytoplasmic structures [18]. An oocyte with "ideal" morphology should present nuclear maturation criteria and have a normal size, cytoplasm, zona pellucida thickness and perivitelline space [16, 19]. According to some authors, it is the combination of all these morphological evaluations that would make it possible to assess, in part, the oocyte quality [16, 21].

The majority of studies evaluating oocyte quality in endometriosis have mainly focused on the immaturity rate of oocytes collected in IVF (i.e. oocytes that cannot be used in practice) and not on the morphological aspect of mature oocytes that can be used for IVF [5]. Nevertheless, some authors have shown a higher prevalence of oocyte morphological alterations, such as the presence of dark central granulations, an abnormal zona pellucida and/or other intra- and extra-cytoplasmic abnormalities [18, 22, 23]. However, these studies were conducted in small samples, and each of them investigated only a limited number of morphological abnormalities. Several publications seem more supportive of an alteration in oocyte quality rather than a defect in endometrial receptivity in the context of endometriosis [5]. Nevertheless, despite a decrease in the number of mature oocytes retrieved and the number of embryos obtained, the rates of clinical pregnancy and delivery in IVF with or without ICSI do not differ in patients with endometriosis compared with unaffected patients [24–27], except in case of deep pelvic endometriosis lesions as suggested by Ashrafi et al. [28].

We aimed with the current study to investigate whether the morphology of mature oocytes obtained in IVF-ICSI may be influenced by the presence of endometriosis in a large cohort of mature oocytes. The secondary objective of this study was to analyze the influence of the characteristics of endometriosis on oocyte morphology.

Material and methods

This is a monocentric retrospective study performed in the IVF unit of the University Hospital of Lille (France).

Study Design and population

Patients were included from the French database JFIV[®] software (version 1.8; RD Services, Langlade, France) over the period January 2007 to December 2019 using the following criteria: women aged 18 to 42 years who

underwent IVF with intracytoplasmic microinjection of ejaculated sperm for sperm alterations.

The following exclusion criteria were applied: patients with polycystic ovary syndrome (according to the recently revised Rotterdam criteria) [29] or any other etiology of anovulation (premature ovarian failure, functional hypothalamic amenorrhea, hyperprolactinemia, other congenital or acquired gonadotropic deficits) or hyperandrogenism (non-classical adrenal hyperplasia, Cushing syndrome), patient with severe or morbid obesity (Body Mass Index (BMI) ≥ 35 kg/m²), karyotype abnormalities in at least one of the two members of the couple, ICSI with surgical sperm in case of azoospermia, patients who underwent complete endometriosis surgery, modified-natural cycle protocol, absence of mature oocytes collected at oocyte retrieval.

The population was divided into two groups according to the notion of a history of endometriosis or not. Control patients had no history of endometriosis. The second group consisted of patients with deep pelvic and/or ovarian endometriosis, operated or not.

As this study was retrospective and without intervention, the opinion of the Ethics Committee on the study was not required. All patients had given prior consent for the use of their clinical, hormonal and ultrasound record. On December 16, 2019, the Institutional Review Board of the Lille University Hospital gave unrestricted approval for the anonymous use of all patients' clinical, hormonal and ultrasound records (reference DEC20150715-0002).

Infertility exploration assessment

The infertility assessment included for all patients: a query on the couple's antecedents and lifestyles, calculation of BMI, hormone assays associated with an ultrasound examination for evaluation of ovarian reserve, search for endometriosis lesions and counting of the antral follicles at the beginning of the follicular phase of the menstrual cycle (between D2 and D5 of the cycle). The ultrasound examination was performed with a Voluson E8 Expert ultrasound machine with an endovaginal probe at 5–9 MHz (General Electric Systems, Velizy, France) according to the "real-time two-dimensional (2D)" procedure [30].

Diagnosis of endometriosis

The diagnosis of endometriosis was made either by endovaginal ultrasound imaging associated with a pelvic Magnetic Resonance Imaging (MRI) performed in our hospital, or surgically with anatomic-pathological confirmation, according to the French National College of Obstetrics and Gynecology (CNGOF) guidelines [8]. Deep endometriosis was defined as described by Collinet et al. [8].

The history of endometriosis surgery consisted of any partial endometriosis surgery. All patients had one or more endometriosis lesions at the time of stimulation.

Biological analysis

The AMH, expressed in pmol/l, was measured prior to any attempt (measurement by the semi-automated 2nd generation AMH-EIA A11893 Immunotech semi-automated enzyme immunoassay kit from Beckman Coulter (Villepinte, France) for samples taken before 01/01/2016, then by the automated Access Dxi B13127 automated assay from Beckman Coulter (Villepinte, France) for samples taken after this date). Due to the different sensitivities of these two techniques, the results were secondarily homogenized using the following conversion formula: $AMH-EIA = (AMH\ Dxi - 0.44) / 0.775$ published by Pigny et al. [31]. Estradiol (chemiluminescence technique, Architect AxSYM[®] multi-parameter biochemical automaton, Abbott Laboratories (Mandaluyong, Philippines)) was evaluated at each control during controlled ovarian stimulation.

Procedures for controlled ovarian hyperstimulation (COH)

Patients received either a long agonist or an antagonist protocol. Daily subcutaneous injections of recombinant FSH (Follicle-stimulating Hormone) or HMG (Human Menopausal Gonadotropin) were performed. The starting dose was selected according to age, BMI, Antral Follicle Count (AFC) and AMH. Ovulation was triggered by subcutaneous injection of 250 μ g of recombinant hCG (Human Chorionic Gonadotropin) (Ovitrelle[®], Merck Serono, Lyon, France) or 0.2 mg of a short half-life GnRH (Gonadotropin Releasing Hormone) agonist (Triptorelin 0.2 mg) if there was a risk of ovarian hyperstimulation syndrome. Thirty-six hours after this injection, trans-vaginal ultrasound-guided oocyte retrieval was performed.

Oocytes morphological evaluation

The evaluation of maturity and oocyte morphology post-decoronation was carried out approximately 2 h after the retrieval just before sperm injection, at X400 magnification using a Leica DMIRB inverted microscope as previously described [32]. In this study, two oocyte morphology scores were used:

- the AOQI (Average Oocyte Quality Index) score established by Sigala et al. [32] in 2015. This score counts the number of abnormalities in oocyte morphology on 7 items (cytoplasmic granularity, zona pellucida anomaly (irregular shape or thickened zona pellucida), presence of intracytoplasmic vacuoles, material in the perivitelline space, anomaly of the first polar body, large perivitelline space, oocyte

shape) and corresponds to the ratio of the total number of abnormalities to the number of metaphase II oocytes collected.

- the MOMS (metaphase II oocyte morphological scoring system) score was calculated for each oocyte. This score published by Rienzi et al. [33] in 2008 attributes a different coefficient to 5 abnormalities depending on their impact on the outcome of the attempts (fertilization rate, rate of zygotes obtained, rate of embryos obtained, pregnancy rates...). The average MOMS scores of the oocytes collected per attempt were then calculated by the ratio of the sum of the MOMS scores of the oocytes to the number of metaphase II oocytes collected on the attempt.

Embryos morphological evaluation

Sperm microinjection using the ICSI technique was performed on each M2 oocyte. An evaluation of normal diploid fertilization was made at 16–18 h after the injection, by observation of the two pronuclei and the second polar body (PB) expelled in the perivitelline space (PVS). Early cleavage was observed 27 h after injection. Embryo quality was estimated at 44–46 h (or 68 h) from injection. Embryo quality classification in our IVF laboratory is based on the number and size of blastomeres, the degree of fragmentation, and the presence or absence of multi-nucleated blastomeres according to the Istanbul Consensus Conference [17]. On day 2, an embryo was considered to be of good quality if it had 4 blastomeres of equal size, without multi-nucleation and with less than 10% fragmentation. If the embryo transfer was to take place on day 3 after injection, a good quality embryo had to have 8 cells of equal size, without multi-nucleation and with less than 10% fragmentation. Only supernumerary embryos of good quality were frozen for subsequent embryo transfers. Following embryo transfer on day 2 or day 3, all supernumerary embryos (i.e. which were not meet criteria for transfer or freezing) were cultured until day 5 or 6.

Outcome of the attempts

The transfer of cleaved-staged embryo(s) was performed at D2 or D3 post-oocyte retrieval. The luteal phase support consisted of daily administration of 600 mg vaginal progesterone or 30 mg dydrogesterone per os in 3 doses started on the evening of the oocyte retrieval. A “freeze-all” strategy of the entire embryonic cohort was implemented when the patient was at risk of ovarian hyperstimulation syndrome or when progesterone levels at the end of stimulation were abnormally high. A

plasma pregnancy test was routinely performed 14 days after embryo transfer. If a pregnancy was confirmed, luteal phase support was maintained until 8 weeks of pregnancy. The comparison of the two groups was based on fertilization rates (number of zygotes obtained / number of metaphase II oocytes), the number of embryos obtained, the percentage of grade 1 embryos and the cumulative number of clinical pregnancies.

Statistical analysis

Categorical parameters were expressed as frequencies and percentages. Continuous parameters were expressed as mean and standard deviation or as median and inter-quartile range. Distribution of continuous parameters were checked graphically and using Shapiro Wilk test.

The comparison of the two groups (Endometriosis vs controls) for the characteristics of the first cycle was performed using a Chi-square test for smoking and using Student t test for continuous parameters.

A linear mixed model was used to compare continuous dependent variables between the two groups, with patient as random effect to take into account for the correlation between the cycles of a same patient. A generalized estimating equation (GEE) model with patient as random effect was used for the others parameters: one GEE model with negative binomial distribution and logit link function (GEE1 model) for the count dependent variables; another one with a binomial distribution and a link logit function (GEE2 model) for the binary dependent variables.

The GEE1 model was performed for the maturation rate, considering the number of MII oocytes as dependent variable and the number of oocytes retrieved as offset; for the fertilization rate, considering the number of zygotes as dependent variable and the number of MII oocytes as offset; for the top embryos rate, considering the number of top embryos as dependent variable and the number of embryos obtained as offset. All offset variables were log-transformed.

A Mann–Whitney U test was used to compare the cumulative implantation rate between two groups. A non-parametric generalized linear model was used to compare the cumulative implantation rate between the endometriosis group vs the control group adjusted on confounding factors.

Analyses were adjusted on the woman’s age, the woman’s smoking status, the body mass index, total dose of FSH, stimulation protocol, stimulation product and the attempt rank (List 1) for the oocyte quality parameters, the fertilization rate, the rate of top embryos, the cumulative pregnancy rate.

Analyses were adjusted on the confounding factors of the List 1 and on the AMH rate for the following

parameters: number of follicles over 15 mm, number of oocytes retrieved, number of MII oocytes, the mature oocytes rate relative to the number of oocytes retrieved, the mature oocytes rate relative to the number of follicles over 15 mm, total number of embryos obtained.

For adjusted analyses, missing parameters values were handled by multiple imputation procedures. Missing data were imputed under the missing at random assumption using a regression switching approach (chained equation with $m = 10$ imputations) with predictive mean matching method for continuous variables and logistic regression (binary, ordinal, or polynomial) for qualitative variables [34]. The imputation procedure were performed using the main baseline characteristics and outcomes, and estimates obtained in the different imputed data sets were combined using the Rubin’s rules [35, 36].

Data were analyzed using the SAS software (SAS Institute Inc, Cary, NC, USA) and all statistical tests were performed with a 2-tailed alpha risk of 0.05.

Results

A total of 175 patients were included in the endometriosis group and 401 in the control group. They were aged between 19 and 41 years, and had been treated with

IVF-ICSI attempts in our IVF unit. Thus, 348 ICSI cycles, corresponding to the morphological evaluation of 2016 metaphase II oocytes, in the endometriosis group and 576 cycles, representing 4073 mature oocytes, in the control group were analyzed.

Table 1 shows the clinical characteristics of the patients at the time of their first IVF-ICSI attempt.

Comparisons of ICSI cycles, embryo quality, and outcome of attempts in control and endometriosis patients are presented in Table 2. The number of cycles that required a freeze-all strategy did not differ between the endometriosis and control groups. A total of 117 cycles did not have embryo transfer, of which 49 were in patients with endometriosis. The stimulation methods differed significantly between the 2 groups in terms of protocol type and gonadotropins used, with more stimulation by agonist protocol and HMG in the endometriosis group. Stimulation duration, total FSH dose, and estradiol level at the triggering day were significantly higher in the endometriosis group compared to the control group. The number of follicles over 15 mm on the day of triggering, total number of retrieved oocytes, number of retrieved metaphase II oocytes, and mature oocytes / number of follicles over 15 mm on ultrasound ratio were

Table 1 Clinical Characteristics of Patients

<i>n</i> _{patientes}	<i>n</i>	Controls N=401	<i>n</i>	Endometriosis N=175	<i>p</i>
Age of woman (years), mean ± SD	401	30.4 ± 3,6	175	31.4 ± 3.6	0.002
Smoking	377	41 (10.9)	164	29 (17,7)	0.030
BMI (kg/m ²), mean ± SD	401	24.4 ± 4.5	162	22.9 ± 3.7	<0.001
AMH (pmol/mL), mean ± SD	399	19.6 ± 12.6	109	17.4 ± 11.3	0.10
Endometriosis Surgery		NA	167	113 (67.7)	NA
Endometrioma(s)		NA	168	80 (47.6)	NA
Deep Pelvic Endometriosis		NA	165	104 (63.0)	NA
No pre-treatment		NA	165	100 (60.6)	NA
Pre-treatment		NA		65 (39.4)	
<i>With GnRH agonists</i>		NA	165	42 (25.4)	NA
<i>With other antigonadotropes</i>		NA		23 (13.9)	NA

Table 2 Characteristics of ICSI cycles and comparison of embryo quality and outcome of attempts between control and endometriosis patients

	n	Controls N=548	n	Endometriosis N=348	p	Adjusted p*
Stimulation protocol, n (%)	547		337		<0.001	NA
Daily agonist protocol		223 (40.8)		175 (51.9)		
Delayed agonist protocol		11 (2.0)		97 (28.8)		
Antagonist protocol		313 (57.2)		65 (19.3)		
Trigger product recombinant hCG n (%) versus GnRH agonist	545	530 (97.2)	346	343 (99.1)	0.051	NA
Duration of stimulation (days)	487	11.2 ± 1.8	345	11.6 ± 1.8	<0.001	NA
Total dose of FSH	542	2507 ± 1330	346	3208 ± 1529	<0.001	NA
Estradiol level on triggering (pg/mL)	500	2242 ± 1034	324	2524 ± 1188	<0.001	NA
Type of exogenous gonadotropin	548		341		< 0.001	NA
Recombinant FSH, n (%)		410 (74.9)		191 (56.0)		
HMG, n (%)		138 (25.1)		150 (44.0)		
Number of follicles greater than 15 mm at ultrasound the day of triggering	520	9.27 ± 3.99	348	7.70 ± 3.60	< 0.001	< 0.001 [†]
Total number of oocytes retrieved	548	10.93 ± 5.60	348	8.55 ± 4.52	< 0.001	< 0.001 [†]
Total number of M2 oocytes retrieved	548	7.43 ± 4.29	348	5.79 ± 3.53	< 0.001	< 0.001 [†]
Mature oocyte / number of follicles over 15 mm	520	0.87 ± 0.62	336	0.77 ± 0.44	0.031	0.56 [†]
Mature oocyte / number of oocytes retrieved	548	0.69 ± 0.21	348	0.69 ± 0.22	0.95	0.82 [†]
Fertilization rate n/n _{MII} ovo (%)	548	2475/4073 (60.8)	348	1233/2014 (61.2)	0.57	0.21
Number of cleaved-staged embryos obtained	548	4.37 ± 3.02	347	3.38 ± 2.47	< 0.001	0.032 [†]
Percentage of grade 1 embryos n/n _{embryos} (%)	522	1419/2394 (59.3)	321	251/1174 (21.4)	< 0.001	<0.001
Cycles with freezing of supernumerary embryos, excluding freeze-all strategy (%)	446	214 (48.0)	293	102 (34.8)	0.0015	0.13
Cumulative clinical pregnancy rate n/n _{cycles} (%)	548	307/548 (57.7)	348	124/348 (35.6)	< 0.001	0.006
Cumulative implantation rate	480	0.34 ± 0.39	299	0.23 ± 0.34	< 0.001	0.034 [†]

Values are presented by mean and standard deviation unless otherwise stated.* adjustment on: age, tobacco, BMI, rank of attempt, stimulation protocol, stimulation product, total dose of FSH administered after 10 imputations to process missing data.† adjustment on AMH in additionhCG: Human Chorionic Gonadotropin ; GnRH: Gonadotropin Releasing Hormone ; FSH: Follicle-Stimulating Hormone ; HMG: Human Menopausal Gonadotropin ; BMI: Body Mass AMH: Antimullerian Hormone ; FSH: Follicle Stimulating Hormone ; M2: Metaphase II ; NA : Not Applicable.

significantly lower in the endometriosis group, even after adjustment. In the endometriosis group, the total number of embryos obtained, the rate of grade 1 embryos, the cumulative clinical pregnancy rate and the cumulative implantation rate were significantly lower than in Controls. These differences remained after adjustment.

Comparison of oocyte morphology according to the history of endometriosis is shown in Table 3. The two groups differed significantly before and after adjustment on the criteria: fragmented first polar body, abnormal oocyte shape, and presence of intracytoplasmic vacuoles. The "presence of perivitelline material" anomaly was significantly greater in the control group, but not after adjustment. No difference on AOQI and MOMS scores was found.

Table 4 shows comparison of oocyte morphology and cycle outcomes according to disease characteristics and COH in the endometriosis group. The history of endometriosis surgery impacted the results with regard to the number of oocytes retrieved and the number of mature oocytes collected. The absence of pre-stimulation treatment was associated with a significantly higher number

of mature oocytes retrieved. Similarly, recombinant FSH stimulation resulted in a statistically higher number of total oocytes and metaphase II oocytes being obtained during oocyte retrieval compared to HMG stimulation.

Details of the morphological oocyte abnormalities according to the characteristics of endometriosis are presented in the [supplemental table](#). Only the presence of endometrioma(s) was significantly associated with oocyte shape abnormalities.

Discussion

To our knowledge, this is the first study comparing AOQI and MOMS oocyte morphological evaluation scores in endometriosis compared to controls in IVF-ICSI.

According to our study, endometriosis does not seem to have a significant impact on oocyte morphology in IVF-ICSI. Although the oocytes from the endometriosis group were more frequently misshapen and had intracytoplasmic vacuoles more often than those from the controls, the first polar body was less often fragmented in this group. In addition, the AOQI and MOMS scores,

Table 3 Comparison of oocyte morphology

	Controls n _{ovo} M2 = 4073	Endometriosis n _{ovo} M2 = 2016	p	Ajusted p*
Fragmented PB1	2365 (58.1)	1079 (53.5)	0.014	0.003
Abnormal ZP (irregular shape or thickened)	90 (2.2)	65 (3.2)	0.17	0.91
Large PVS	466 (11.4)	270 (13.4)	0.34	0.89
Peri-Vitelline material	909 (22.3)	385 (19.1)	0.039	0.093
Abnormal oocyte shape	79 (1.9)	121 (6.0)	<0.001	<0.001
Granular cytoplasm	394 (9.7)	290 (14.4)	0.064	0.31
Intracytoplasmic vacuoles	56 (1.4)	46 (2.3)	0.043	0.004
AOQI Score, median [Q1 – Q3]**	1.00 [0.72 – 1.40]	1.00 [0.60 – 1.47]	0.46	0.084
MOMS Score, median [Q1 – Q3]**	1.48 [1.00 – 2.00]	1.45 [0.87 – 2.00]	0.29	0.053

Values are presented by number of oocytes and percentage, unless otherwise stated. No missing data for these parameters.* adjustment for: age, smoking, BMI, AMH, rank of attempt, stimulation protocol, stimulation product, total dose of FSH administered** the values are calculated at cycle level PB1: First Polar Body ; ZP: Zona Pellucida ; PVS: Péri-Vitelline Space ; AOQI: Average Oocyte Quality Index ; MOMS: metaphase Iloocyte morphological scoring system ; BMI: Body Mass Index ; AMH: Antimullerian Hormone ; FSH: Follicle Stimulating Hormone

known to assess oocyte morphology, did not differ between the two groups [32, 33]. These results disagree with those previously published. Indeed, Kasapoglu et al. [37], in a retrospective analysis of 1,568 mature oocytes, found a significant increase in morphological abnormalities of the cytoplasm, the zona pellucida and the first polar body in patients with endometriosis compared to controls. Similarly, Shebl et al. [38], in a cohort of 2,343 mature oocytes, have observed a lower number of oocytes with normal morphology in their endometriosis group. In the current study, we preferred to consider all the oocyte abnormalities listed in the MOMS and AOQI scores and not focus on only some of them.

The impact of oocyte morphology on the results of IVF-ICSI is still debated [18]. The meta-analysis of Setti et al. [39] claimed that fertilization rates are significantly associated with the absence of 4 oocyte morphological abnormalities (first polar body and perivitelline space enlarged, refractive bodies and intracytoplasmic vacuoles). These hypotheses are supported by other publications [18, 33, 40–43]. Regarding the aspect of the first polar body, some publications argued that its shape may have more impact on IVF outcomes than its fragmentation [18, 22, 41, 43]. For other authors, the thickness of the zona pellucida also

seems to affect the potential for embryonic development [44, 45]. Conversely, other experts assert that the morphology of the first polar body, the size of the perivitelline space and the appearance of the zona pellucida are only phenotypic variations that are more likely to be due to in vitro culture conditions and/or female age, without any real impact on IVF results [16–18]. Furthermore, Ten et al. [46] described increased chances of obtaining good quality embryos in case of a larger perivitelline space. The retrospective study of Chamayou et al. [47] and the prospective analysis of Ashrafi et al. [48] concluded that oocyte dysmorphisms probably have an impact on fertilization rates, but not on implantation or pregnancy rates in IVF-ICSI. Thus, morphological study of the oocyte provides only partial information on the potential for fertilization and embryonic development.

Apart from the analysis of oocyte morphology, other more invasive procedures have been proposed to evaluate oocyte quality: meiotic spindle analysis, oocyte mitochondrial capital assessment, cytogenetic and molecular analysis of first polar body [5, 49–52]. Their relevance is still controversial. Nevertheless, in case of endometriosis, some studies have shown an increased risk of chromosomal misalignment leading to increased rates of aneuploidy [5, 23,

Table 4 Comparison of oocyte morphology and cycle outcomes according to disease and stimulation characteristics in the endometriosis group

	Endometrioma(s) n=156	No Endometrioma(s) n=182	Deep Pelvic Endometriosis n=167	No Deep Pelvic Endometriosis n=161	Endometriosis Surgery n=231	No Endometriosis Surgery n=107	No pre-treatment n=219	Pre-treatment with GnRH agonists n=92	Pre-treatment with other antigonadotropic hormones n=52	P	Daily agonist protocol n=175	Delayed agonist protocol n=97	Antagonist protocol n=65	P	Recombinant FSH n=191	HMG n=150	P
Total number of oocytes retrieved	8.06 ± 4.60	9.03 ± 4.49	8.64 ± 4.65	8.42 ± 4.55	8.16 ± 4.47	9.58 ± 4.57	9.01 ± 4.82	7.77 ± 3.77	7.87 ± 4.05	0.051	8.70 ± 4.63	8.08 ± 4.18	8.69 ± 4.74	0.65	9.29 ± 4.66	7.58 ± 4.18	< 0.001
Total number of M2 oocytes	5.54 ± 3.60	6.12 ± 3.48	5.97 ± 3.71	5.62 ± 3.43	5.52 ± 3.42	6.55 ± 3.72	6.13 ± 3.62	5.31 ± 3.17	5.38 ± 3.50	0.021	5.86 ± 3.64	5.60 ± 3.42	5.78 ± 3.43	0.84	6.25 ± 3.61	5.19 ± 3.38	0.014
AQOI score, median [Q1 – Q3]*	1.00 [0.54 – 1.52]	1.00 [0.67 – 1.33]	1.00 [0.67 – 1.33]	1.00 [0.57 – 1.50]	1.00 [0.60 – 1.38]	1.00 [0.63 – 1.57]	1.00 [0.63 – 1.57]	1.00 [0.50 – 1.29]	1.00 [0.54 – 1.23]	0.18	1.00 [0.60 – 1.50]	1.00 [0.57 – 1.29]	1.00 [0.64 – 1.63]	0.23	1.00 [0.60 – 1.57]	1.00 [0.50 – 1.33]	0.21
MOMS score, median [Q1 – Q3]*	1.38 [0.80 – 1.93]	1.48 [0.97 – 2.00]	1.47 [0.86 – 2.00]	1.43 [0.90 – 2.00]	1.40 [0.86 – 2.00]	1.60 [1.00 – 2.00]	1.47 [0.93 – 2.00]	1.37 [0.67 – 2.00]	1.43 [0.99 – 1.89]	0.45	1.48 [0.97 – 2.00]	1.27 [0.68 – 1.95]	1.42 [0.88 – 2.00]	0.27	1.60 [0.93 – 2.00]	1.34 [0.70 – 1.95]	0.13
Cumulative clinical pregnancy rate n/n _{cases} %	53/156 (34.0)	69/182 (37.9)	58/167 (34.7)	62/161 (38.5)	79/231 (34.2)	41/107 (38.3)	87/219 (39.7)	17/62 (27.4)	17/52 (32.7)	0.18	66/175 (37.7)	33/97 (34.0)	23/65 (35.4)	0.93	73/191 (38.2)	49/150 (32.7)	0.42
Cumulative implantation rate	0.22 ± 0.34	0.23 ± 0.34	0.20 ± 0.32	0.25 ± 0.36	0.22 ± 0.34	0.22 ± 0.34	0.23 ± 0.34	0.17 ± 0.29	0.25 ± 0.39	0.61	0.24 ± 0.35	0.21 ± 0.33	0.21 ± 0.34	0.88	0.23 ± 0.33	0.23 ± 0.36	0.71

Values are presented by mean and standard deviation unless otherwise stated.* Values are calculated at cycle level/AQOI: Average Oocyte Quality Index ; MOMS: metaphase II oocyte morphological scoring system ; M2: Metaphase II ; GnRH: Gonadotropin Releasing Hormone ; FSH: Follicle-Stimulating Hormone ; HMG: Human Menopausal Gonadotropin

53, 54]. Using the transmission electron microscopy technique, some authors have described a lower mitochondrial content in oocyte cytoplasm of endometriosis patients [5, 49]. Other authors, in cytogenetic studies performed using fluorescence in situ hybridization (FISH) on first polar bodies, have found abnormalities in the segregation of certain autosomes in patients with endometriosis [52].

Concerning our secondary objectives, the presence of deep pelvic endometriosis lesions or endometrioma(s) had no deleterious impact on either the global oocyte morphology or the success rates of IVF-ICSI attempts in the endometriosis group. These findings of no impact of the presence of endometrioma(s) on the results of IVF-ICSI are consistent with what has been previously published [27, 55–59]. Interestingly, analysis of the details of oocyte morphological abnormalities found significantly more misshapen oocytes in the subgroup of patients with endometrioma(s), without impacting the AOQI and MOMS scores (data presented in the [supplemental table](#)). Some authors suggest that the presence of endometrioma(s) may induce local pelvic inflammation and higher oxidative stress in the ovarian cortex, which may alter follicular and oocyte development and therefore potentially the oocyte morphology [60, 61].

The number of follicles over 15 mm, the number of retrieved oocytes and the number of mature oocytes were significantly lower in the endometriosis group, as previously described by other authors [5, 38]. Likewise, endometriosis group had significantly fewer embryos obtained, fewer good quality embryos and significantly lower cumulative clinical pregnancy, probably as a result of a significantly lower number of mature oocytes retrieved. Most of previous publications also report a lower number of mature oocytes and embryos in the case of endometriosis [5, 38, 59, 62]. Nevertheless, Juneau et al. [63], in a large retrospective study using the preimplantation genetic screening (PGS) technique, found similar embryonic aneuploidy rates between endometriosis and controls.

In our study, the lower cumulative clinical pregnancy and implantation rates in the endometriosis group may be explained more by reduced implantation capacity in patients with endometriosis than by impaired oocyte quality, as recently reported in several studies [64–66].

The statistical analysis of the outcomes of IVF-ICSI attempts according to the stimulation protocols in the endometriosis group seems to indicate a neutral impact of pre-treatment with GnRH agonists, combined oral or non-oral contraceptives or high dose of progestogens prior to the attempt on oocyte morphology. Moreover, the use of one of these 3 pre-treatments does not seem to have a negative impact on the cumulative clinical pregnancy rates. Other authors claimed a possible significant increase of pregnancy rates when using GnRH agonist

pre-treatment or combined oral or non-oral contraceptives prior to IVF ± ICSI [59], as it was recently highlighted by De Ziegler et al. [67].

In our unit, we still use the policy of embryo transfer on day 2 or 3 because the evidence of an increasing of clinical or live pregnancy rate following fresh blastocyst transfer in comparison with a fresh cleavage stage transfer are low [68, 69]. Despite a recent study [70] suggesting better cumulative live birth change using blastocyst stage transfer strategy, there is to date no consensus about the first line transfer-policy due to conflicting results. Indeed, the cumulative pregnancy rate derived from fresh and frozen-thawed cycles following a single oocyte retrieval are usually similar between day 2 or day 3 transfer and blastocyst transfer [71].

The principal limitation of our study results from the retrospective design of the analysis. But the strength is that the analysis included more than 6,000 metaphase II oocytes, of which more than 2,000 were from endometriosis patients. Thus, in our knowledge, this is the largest study to have analyzed so precisely the morphology of mature oocytes using seven criteria and two scores in women with endometriosis undergoing IVF-ICSI. Moreover, because histologic or laparoscopic confirmation was not required to determine the presence or absence of endometriosis, some patients in the control group may in fact have a paucisymptomatic endometriosis that was not detected by US or MRI. Nevertheless, these procedures were performed by experienced clinicians in the detection of endometriosis lesions, as we manage a large population of women with this disease in our university hospital.

In the current study, endometriosis patients were significantly older, thinner and more often smokers than the control patients. Lower BMI in patients with endometriosis has already been reported in epidemiological studies [72, 73]. The association between smoking and endometriosis is controversial in the literature [73]. Furthermore, age difference between the two groups is probably related to the delay imposed by the diagnosis and exploration of endometriosis before IVF attempt. Nevertheless, from a clinical point of view, a difference of one year and/or 1.5 kg/m² of BMI does not seem to have a significant impact in clinical practice. Similarly, the percentage of patients who smoked remains low in both groups. Moreover, the adjustment made to the statistical results took into account, among other factors, these 3 criteria, which allowed a reliable comparison of the two groups.

Conclusion

In conclusion, endometriosis does not seem to have a negative impact on oocyte morphology in IVF-ICSI. Despite experimental data suggesting a decrease in intrinsic oocyte quality in patients with endometriosis, this cannot be unraveled by the study of oocyte

morphology. The use of other sophisticated but invasive methods could be more appropriate to assess oocyte quality in women with endometriosis. Moreover, the development of other non-invasive methods that can be used routinely may provide additional information.

Abbreviations

IVF: In Vitro Fertilization; ICSI: Intracytoplasmic Sperm Injection; AOQI: Average Oocyte Quality Index; MOMS: Metaphase II Oocyte Morphological Scoring System; BMI: Body Mass Index; MRI: Magnetic Resonance Imaging; CNGOF: French National College of Ob-Gyn; AMH: Anti-Müllerian Hormone; COH: Controlled Ovarian Hyperstimulation; FSH: Follicle Stimulating Hormone; HMG: Human Menopausal Gonadotropin; AFC: Antral Follicle Count; hCG: Human Chorionic Gonadotropin; GnRH: Gonadotropin Releasing Hormone; PB: Polar Body; PVS: Perivitelline Space; GEE: Generalized Estimating Equation; FISH: Fluorescence in situ hybridization.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12958-021-00798-x>.

Additional file 1:

Acknowledgements

We thank Pr Dewailly for his assistance in critical discussion and Dr Bailly for her help in data collection.

Authors' contributions

Each author acknowledges that he or she participated sufficiently in the work to take public responsibility for its content. All the authors give their agreement to submission of the manuscript.

Funding

The authors did not receive support from any organization for the submitted work.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethical approval and consent to participate

On December 16, 2019, the Institutional Review Board of the Lille University Hospital gave unrestricted approval for the anonymous use of all patients' clinical, hormonal and ultrasound records (reference DEC20150715-0002). Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Competing interest

The authors have no conflict of interest to declare.

Author details

¹Service de Gynécologie Endocrinienne Et Médecine de La Reproduction, CHU Lille, Assistance Médicale À La Procréation Et Préservation de La Fertilité, Hôpital Jeanne de Flandre, Service d'Avenue Eugène Avinée, 59000 Lille, France. ²Institut de Biologie de La Reproduction-Spermiologie-CECOS, Hôpital Jeanne de Flandre, Centre Hospitalier Et Universitaire, 59000 Lille, France. ³EA 4308 Gamétogenèse Et Qualité du Gamète, Faculté de Médecine Et CHU de Lille, F-59000 Lille, France. ⁴EA 2694, Santé Publique : Épidémiologie Et Qualité Des Soins, Univ. Lille, CHU Lille, Unité de Biostatistiques, F-59000 Lille, France. ⁵Service de Chirurgie Gynécologique, Hôpital Jeanne de Flandre, Centre

Hospitalier Et Universitaire, 59000 Lille, France. ⁶Faculté de Médecine, Université de Lille, 59045 Lille, France.

Received: 12 April 2021 Accepted: 11 July 2021

Published online: 16 October 2021

References

- Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. *Endocr Rev*. 2019;40(4):1048–79.
- Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Vigano P. Endometriosis *Nat Rev Dis Primers*. 2018;4(1):9.
- Dumesic DA, Meldrum DR, Katz-Jaffe MG, Krisher RL, Schoolcraft WB. Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health. *Fertil Steril*. 2015;103(2):303–16.
- Mate G, Bernstein LR, Torok AL. Endometriosis Is a Cause of Infertility. Does Reactive Oxygen Damage to Gametes and Embryos Play a Key Role in the Pathogenesis of Infertility Caused by Endometriosis? *Front Endocrinol (Lausanne)*. 2018;9:725.
- Sanchez AM, Vanni VS, Bartiromo L, Papaleo E, Zilberberg E, Candiani M, et al. Is the oocyte quality affected by endometriosis? A review of the literature. *J Ovarian Res*. 2017;10(1):43.
- American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil Steril*. 1997;67(5):817–21.
- Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, et al. World Endometriosis Society consensus on the classification of endometriosis. *Hum Reprod*. 2017;32(2):315–24.
- Collinet P, Fritel X, Revel-Delhom C, Ballester M, Bolze PA, Borghese B, et al. Management of endometriosis: CNGOF/HAS clinical practice guidelines - Short version. *J Gynecol Obstet Hum Reprod*. 2018;47(7):265–74.
- Donnez J, Van Langendonck A, Casanas-Roux F, Van Gossom JP, Pirard C, Jadoul P, et al. Current thinking on the pathogenesis of endometriosis. *Gynecol Obstet Invest*. 2002;54 Suppl 1:52–8; discussion 9–62.
- Patel BG, Lenk EE, Lebovic DI, Shu Y, Yu J, Taylor RN. Pathogenesis of endometriosis: Interaction between Endocrine and inflammatory pathways. *Best Pract Res Clin Obstet Gynaecol*. 2018;50:50–60.
- Borghese B, Santulli P, Marcellin L, Chapron C. Definition, description, clinicopathological features, pathogenesis and natural history of endometriosis: CNGOF-HAS Endometriosis Guidelines. *Gynecol Obstet Fertil Senol*. 2018;46(3):156–67.
- Broi MGD, Ferriani RA, Navarro PA. Ethio-pathogenic mechanisms of endometriosis-related infertility. *JBRA Assist Reprod*. 2019;23(3):273–80.
- Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: pathophysiology and management. *Lancet*. 2010;376(9742):730–8.
- Tomassetti C, D'Hooghe T. Endometriosis and infertility: Insights into the causal link and management strategies. *Best Pract Res Clin Obstet Gynaecol*. 2018;51:25–33.
- Bouet PE, Chao de la Barca JM, Bouclet R, Descamps P, Legendre G, Hachem HE, et al. Elevated Levels of Monocyte Chemoattractant Protein-1 in the Follicular Fluid Reveals Different Population among Women with Severe Endometriosis. *J Clin Med*. 2020;9(5).
- Rienzi L, Balaban B, Ebner T, Mandelbaum J. The oocyte. *Hum Reprod*. 2012;27(Suppl 1):i2–21.
- Alpha Scientists in Reproductive M, Embryology ESIGo. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. *Hum Reprod*. 2011;26(6):1270–83.
- Rienzi L, Vajta G, Ubaldi F. Predictive value of oocyte morphology in human IVF: a systematic review of the literature. *Hum Reprod Update*. 2011;17(1):34–45.
- Swain JE, Pool TB. ART failure: oocyte contributions to unsuccessful fertilization. *Hum Reprod Update*. 2008;14(5):431–46.
- Van Blerkom J, Henry G. Oocyte dysmorphism and aneuploidy in meiotically mature human oocytes after ovarian stimulation. *Hum Reprod*. 1992;7(3):379–90.
- Lazzaroni-Tealdi E, Barad DH, Albertini DF, Yu Y, Kushnir VA, Russell H, et al. Oocyte Scoring Enhances Embryo-Scoring in Predicting Pregnancy Chances with IVF Where It Counts Most. *PLoS One*. 2015;10(12):e0143632.

22. Ceviren AKON, Urfan A, Donmez L, Isikoglu M. Characteristic cytoplasmic morphology of oocytes in endometriosis patients and its effect on the outcome of assisted reproduction treatments cycles. *IVF Lite*. 2014;1:88–93.
23. Goud PT, Goud AP, Joshi N, Puscheck E, Diamond MP, Abu-Soud HM. Dynamics of nitric oxide, altered follicular microenvironment, and oocyte quality in women with endometriosis. *Fertil Steril*. 2014;102(1):151–9 e5.
24. Gonzalez-Comadran M, Schwarze JE, Zegers-Hochschild F, Souza MD, Carreras R, Checa MA. The impact of endometriosis on the outcome of Assisted Reproductive Technology. *Reprod Biol Endocrinol*. 2017;15(1):8.
25. Murta M, Machado RC, Zegers-Hochschild F, Checa MA, Sampaio M, Geber S. Endometriosis does not affect live birth rates of patients submitted to assisted reproduction techniques: analysis of the Latin American Network Registry database from 1995 to 2011. *J Assist Reprod Genet*. 2018;35(8):1395–9.
26. Sharma S, RoyChoudhury S, Bathwal S, Bhattacharya R, Kalapahar S, Chattopadhyay R, et al. Pregnancy and Live Birth Rates Are Comparable in Young Infertile Women Presenting with Severe Endometriosis and Tubal Infertility. *Reprod Sci*. 2020;27(6):1340–9.
27. Yang C, Geng Y, Li Y, Chen C, Gao Y. Impact of ovarian endometrioma on ovarian responsiveness and IVF: a systematic review and meta-analysis. *Reprod Biomed Online*. 2015;31(1):9–19.
28. Ashrafi M, Arabipour A, Hemat M, Salman-Yazdi R. The impact of the localisation of endometriosis lesions on ovarian reserve and assisted reproduction techniques outcomes. *J Obstet Gynaecol*. 2019;39(1):91–7.
29. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod*. 2018;33(9):1602–18.
30. Coelho Neto MA, Ludwin A, Borrell A, Benacerraf B, Dewailly D, da Silva CF, et al. Counting ovarian antral follicles by ultrasound: a practical guide. *Ultrasound Obstet Gynecol*. 2018;51(1):10–20.
31. Pigny P, Gorisse E, Ghulam A, Robin G, Catteau-Jonard S, Duhamel A, et al. Comparative assessment of five serum antimullerian hormone assays for the diagnosis of polycystic ovary syndrome. *Fertil Steril*. 2016;105(4):1063–9 e3.
32. Sigala J, Sifer C, Dewailly D, Robin G, Bruyneel A, Ramdane N, et al. Is polycystic ovarian morphology related to a poor oocyte quality after controlled ovarian hyperstimulation for intracytoplasmic sperm injection? Results from a prospective, comparative study. *Fertil Steril*. 2015;103(1):112–8.
33. Rienzi L, Ubaldi FM, Iacobelli M, Minasi MG, Romano S, Ferrero S, et al. Significance of metaphase II human oocyte morphology on ICSI outcome. *Fertil Steril*. 2008;90(5):1692–700.
34. Van Buuren S G-OK. MICE: Multivariate Imputation by Chained Equation in R. *Journal of Statistical Software*. 2011;45(3).
35. Li KM, XL.; Raghunathan, TE.; Rubin, DB.; Significance levels from repeated p-values with multiply-imputed data. *Statistica Sinica*. 1991;1:65–92.
36. Rubin D. Multiple imputation for nonresponse in surveys. *Wiley Series in probability and mathematical statistics*: John Wiley & Sons; 1987.
37. Kasapoglu I, Kuspinar G, Saribal S, Turk P, Avci B, Uncu G. Detrimental effects of endometriosis on oocyte morphology in intracytoplasmic sperm injection cycles: a retrospective cohort study. *Gynecol Endocrinol*. 2018;34(3):206–11.
38. Shebl O, Sifferlinger I, Habelsberger A, Oppelt P, Mayer RB, Petek E, et al. Oocyte competence in vitro fertilization and intracytoplasmic sperm injection patients suffering from endometriosis and its possible association with subsequent treatment outcome: a matched case-control study. *Acta Obstet Gynecol Scand*. 2017;96(6):736–44.
39. Setti AS, Figueira RC, Braga DP, Colturato SS, Iaconelli A Jr, Borges E Jr. Relationship between oocyte abnormal morphology and intracytoplasmic sperm injection outcomes: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2011;159(2):364–70.
40. Braga DP, Setti AS, Figueira Rde C, Machado RB, Iaconelli A Jr, Borges E Jr. Influence of oocyte dysmorphisms on blastocyst formation and quality. *Fertil Steril*. 2013;100(3):748–54.
41. Navarro PA, de Araujo MM, de Araujo CM, Rocha M, dos Reis R, Martins W. Relationship between first polar body morphology before intracytoplasmic sperm injection and fertilization rate, cleavage rate, and embryo quality. *Int J Gynaecol Obstet*. 2009;104(3):226–9.
42. Takahashi H, Otsuki J, Yamamoto M, Saito H, Hirata R, Habara T, et al. Clinical outcomes of MII oocytes with refractile bodies in patients undergoing ICSI and single frozen embryo transfer. *Reprod Med Biol*. 2020;19(1):75–81.
43. Ubaldi F, Rienzi L. Morphological selection of gametes. *Placenta*. 2008;29 Suppl B:115–20.
44. Rama Raju GA, Prakash GJ, Krishna KM, Madan K. Meiotic spindle and zona pellucida characteristics as predictors of embryonic development: a preliminary study using PolScope imaging. *Reprod Biomed Online*. 2007;14(2):166–74.
45. Xu H, Deng K, Luo Q, Chen J, Zhang X, Wang X, et al. High Serum FSH is Associated with Brown Oocyte Formation and a Lower Pregnancy Rate in Human IVF Practice. *Cell Physiol Biochem*. 2016;39(2):677–84.
46. Ten J, Mendiola J, Vioque J, de Juan J, Bernabeu R. Donor oocyte dysmorphisms and their influence on fertilization and embryo quality. *Reprod Biomed Online*. 2007;14(1):40–8.
47. Chamayou S, Ragolia C, Alecci C, Storaci G, Maglia E, Russo E, et al. Meiotic spindle presence and oocyte morphology do not predict clinical ICSI outcomes: a study of 967 transferred embryos. *Reprod Biomed Online*. 2006;13(5):661–7.
48. Ashrafi M, Karimian L, Eftekhari-Yazdi P, Hasani F, Arabipour A, Bahmanabadi A, et al. Effect of oocyte dysmorphisms on intracytoplasmic sperm injection cycle outcomes in normal ovarian responders. *J Obstet Gynaecol Res*. 2015;41(12):1912–20.
49. Xu B, Guo N, Zhang XM, Shi W, Tong XH, Iqbal F, et al. Oocyte quality is decreased in women with minimal or mild endometriosis. *Sci Rep*. 2015;5:10779.
50. Petersen CG, Oliveira JB, Mauri AL, Massaro FC, Baruffi RL, Pontes A, et al. Relationship between visualization of meiotic spindle in human oocytes and ICSI outcomes: a meta-analysis. *Reprod Biomed Online*. 2009;18(2):235–43.
51. Kilani S, Cooke S, Tilia L, Chapman M. Does meiotic spindle normality predict improved blastocyst development, implantation and live birth rates? *Fertil Steril*. 2011;96(2):389–93.
52. Gianaroli L, Magli MC, Cavallini G, Crippa A, Capoti A, Resta S, et al. Predicting aneuploidy in human oocytes: key factors which affect the meiotic process. *Hum Reprod*. 2010;25(9):2374–86.
53. Tilia L, Venetis C, Kilani S, Cooke S, Chapman M. Is oocyte meiotic spindle morphology associated with embryo ploidy? A prospective cohort study. *Fertil Steril*. 2016;105(4):1085–92 e7.
54. Wang WH, Meng L, Hackett RJ, Odenbourg R, Keefe DL. The spindle observation and its relationship with fertilization after intracytoplasmic sperm injection in living human oocytes. *Fertil Steril*. 2001;75(2):348–53.
55. Demirel C, Bastu E, Aydogdu S, Donmez E, Benli H, Tuysuz G, et al. The Presence of Endometrioma Does Not Impair Time-Lapse Morphokinetic Parameters and Quality of Embryos: A Study On Sibling Oocytes. *Reprod Sci*. 2016;23(8):1053–7.
56. Filippi F, Benaglia L, Paffoni A, Restelli L, Vercellini P, Somigliana E, et al. Ovarian endometriomas and oocyte quality: insights from in vitro fertilization cycles. *Fertil Steril*. 2014;101(4):988–93 e1.
57. Hamdan M, Dunselman G, Li TC, Cheong Y. The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis. *Hum Reprod Update*. 2015;21(6):809–25.
58. Nakagawa K, Hisano M, Sugiyama R, Yamaguchi K. Measurement of oxidative stress in the follicular fluid of infertility patients with an endometrioma. *Arch Gynecol Obstet*. 2016;293(1):197–202.
59. Santulli P, Collinet P, Fritel X, Canis M, d'Argent EM, Chauffour C, et al. Management of assisted reproductive technology (ART) in case of endometriosis related infertility: CNGOF-HAS Endometriosis Guidelines. *Gynecol Obstet Fertil Senol*. 2018;46(3):373–5.
60. Matsuzaki S, Schubert B. Oxidative stress status in normal ovarian cortex surrounding ovarian endometriosis. *Fertil Steril*. 2010;93(7):2431–2.
61. Kitajima M, Dolmans MM, Donnez O, Masuzaki H, Soares M, Donnez J. Enhanced follicular recruitment and atresia in cortex derived from ovaries with endometriomas. *Fertil Steril*. 2014;101(4):1031–7.
62. Boucret L, Bouet PE, Riou J, Legendre G, Delbos L, Hachem HE, et al. Endometriosis Lowers the Cumulative Live Birth Rates in IVF by Decreasing the Number of Embryos but Not Their Quality. *J Clin Med*. 2020;9(8).
63. Juneau C, Kraus E, Werner M, Franasiak J, Morin S, Patounakis G, et al. Patients with endometriosis have aneuploidy rates equivalent to their

- age-matched peers in the in vitro fertilization population. *Fertil Steril*. 2017;108(2):284–8.
64. Sanchez AM, Pagliardini L, Cermisoni GC, Privitera L, Makieva S, Alteri A, et al. Does Endometriosis Influence the Embryo Quality and/or Development? Insights from a Large Retrospective Matched Cohort Study. *Diagnostics (Basel)*. 2020;10(2).
65. Blank C, Deboever C, Decroos E, DeCruo I, Tilleman K, De Sutter P, et al. Impaired implantation in endometriosis compared with couples with male subfertility after transfer of equal quality embryos: a matched cohort study. *Reprod Biomed Online*. 2021;42(1):165–74.
66. Bouet PE, Chao de la Barca JM, El Hachem H, Descamps P, Legendre G, Reynier P, et al. Metabolomics shows no impairment of the microenvironment of the cumulus-oocyte complex in women with isolated endometriosis. *Reprod Biomed Online*. 2019;39(6):885–92.
67. de Ziegler D, Pirtea P, Carbonnel M, Poulain M, Cicinelli E, Bulletti C, et al. Assisted reproduction in endometriosis. *Best Pract Res Clin Endocrinol Metab*. 2019;33(1):47–59.
68. Glujovsky D, Farquhar C, Quinteiro Retamar AM, Alvarez Sedo CR, Blake D. Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. *Cochrane Database Syst Rev*. 2016(6):CD002118.
69. Neuhausser WM, Vaughan DA, Sakkas D, Hacker MR, Toth T, Penzias A. Non-inferiority of cleavage-stage versus blastocyst-stage embryo transfer in poor prognosis IVF patients (PRECISE trial): study protocol for a randomized controlled trial. *Reprod Health*. 2020;17(1):16.
70. De Croo I, Colman R, De Sutter P, Tilleman K. Blastocyst transfer for all? Higher cumulative live birth chance in a blastocyst-stage transfer policy compared to a cleavage-stage transfer policy. *Facts Views Vis Obgyn*. 2019;11(2):169–76.
71. De Vos A, Van Landuyt L, Santos-Ribeiro S, Camus M, Van de Velde H, Tourmaye H, et al. Cumulative live birth rates after fresh and vitrified cleavage-stage versus blastocyst-stage embryo transfer in the first treatment cycle. *Hum Reprod*. 2016;31(11):2442–9.
72. Matalliotakis IM, Cakmak H, Fragouli YG, Goumenou AG, Mahutte NG, Arici A. Epidemiological characteristics in women with and without endometriosis in the Yale series. *Arch Gynecol Obstet*. 2008;277(5):389–93.
73. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Management. *Curr Obstet Gynecol Rep*. 2017;6(1):34–41.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

